Canada’s CGPA Welcomes Move Towards National Pharmacare
Budget Announcement Commits To Legislation By The End Of Next Year
A renewed commitment from Canada’s government to a universal national pharmacare program, included in the latest federal budget, has been welcomed by the country’s generics and biosimilars industry.
You may also be interested in...
The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.
A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.